Related Experiment Videos
Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis
Insights
Lovastatin and simvastatin effectively lowered cholesterol and apolipoprotein B in hemodialysis patients. These statins improved lipid profiles, showing significant reductions in LDL cholesterol and VLDL cholesterol.
Area of Science:
- Cardiovascular Pharmacology
- Nephrology and Dialysis
Background:
- Hypercholesterolemia and hypertriglyceridemia are common in hemodialysis patients.
- Statins, such as lovastatin and simvastatin, are HMG-CoA reductase inhibitors used to manage dyslipidemia.
Purpose of the Study:
- To evaluate the efficacy of lovastatin and simvastatin in treating hypercholesterolemia and hypertriglyceridemia in hemodialysis patients.
Main Methods:
- A randomized controlled trial involving 40 hemodialysis patients with hypercholesterolemia.
- Patients received either lovastatin or simvastatin for three months after a four-week placebo period.
- Dosages were gradually increased over the treatment period.
Main Results:
- Both lovastatin and simvastatin significantly reduced total cholesterol, LDL cholesterol, and apolipoprotein B levels.
- Significant reductions in VLDL cholesterol were observed with both drugs.
- The ratio of triglycerides to cholesterol in VLDL increased, indicating altered VLDL composition.
Conclusions:
- Lovastatin and simvastatin are effective in managing dyslipidemia in hemodialysis patients.
- These statins demonstrate a favorable impact on lipid profiles, including reductions in atherogenic lipoproteins.
- Further research may explore long-term cardiovascular outcomes in this population.
Abstract:
The efficacy of lovastatin and simvastatin, competitive inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A reductase, was investigated in 40 hemodialysis (HD) patients displaying hypercholesterolemia and moderate hypertriglyceridemia (selection of 40 patients required screening of 700 hemodialysis patients). After a four-week placebo period, lovastatin or simvastatin was administered to two groups of 20 patients in increasing doses over a period of three months. Thirty-six patients completed the study. Lovastatin (1st month 20 mg; 2nd and 3rd months 40 mg day-1) and simvastatin (1st month 10 mg, 2nd month 20 mg and 3rd month 40 mg day-1) reduced total serum cholesterol from 280.3 +/- 9.4 to 213.0 +/- 6.7 (-24%) and 295.0 +/- 12.2 to 202.3 +/- 8.9 mg/dl (-31.4%), LDL cholesterol from 161.9 +/- 10.7 to 112.1 +/- 7.9 (-30.8%) and 181.8 +/- 14.7 to 107.4 +/- 8.1 mg/dl (-40.9%), as well as apolipoprotein B (apo B) from 116.0 +/- 6.6 to 83.3 +/- 3.7 (-28.2%) and 134.4 +/- 8.2 to 84.1 +/- 5.3 mg/dl (-37.4%), respectively. Furthermore, the ratio of LDL apo B/LDL cholesterol increased significantly (0.63 +/- 0.02 vs. 0.71 +/- 0.05 and 0.63 +/- 0.02 vs. 0.66 +/- 0.02, respectively). Another remarkable effect was the reduction of cholesterol concentration in VLDL (72.4 +/- 8.9 vs. 47.3 +/- 6.8 [lovastatin] and 78.3 +/- 11.1 vs. 50.7 +/- 8.8 mg/dl [simvastatin], respectively). Therefore, the ratio of triglycerides/cholesterol in VLDL increased (3.2 +/- 0.2 vs. 3.8 +/- 0.3 and 3.2 +/- 0.2 vs. 4.0 +/- 0.2, respectively), indicating VLDL formation poor in cholesterol and rich in triglycerides.(ABSTRACT TRUNCATED AT 250 WORDS)